282 related articles for article (PubMed ID: 26678617)
1. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in
Jiménez-Franco LD; Glatting G; Prasad V; Weber WA; Beer AJ; Kletting P
J Nucl Med; 2021 Jan; 62(1):92-98. PubMed ID: 32646878
[TBL] [Abstract][Full Text] [Related]
3. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
Kletting P; Schuchardt C; Kulkarni HR; Shahinfar M; Singh A; Glatting G; Baum RP; Beer AJ
PLoS One; 2016; 11(9):e0162303. PubMed ID: 27611841
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
6. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
7. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
[TBL] [Abstract][Full Text] [Related]
8. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
9. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
10. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
[TBL] [Abstract][Full Text] [Related]
12. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
13. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
14. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
16. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]